DEA Okays Fentanyl Importer License for Vici Health Sciences LLC
Published Date: 1/28/2025
Notice
Summary
Vici Health Sciences, LLC wants to become an official importer of certain controlled substances, including fentanyl-related compounds. This affects companies and people involved in drug manufacturing and import, who can comment or request a hearing by February 27, 2025. No direct money changes are mentioned, but this registration could impact how these substances enter the U.S. market.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Importer application for fentanyl compounds
Vici Health Sciences, LLC applied on October 4, 2024 to be registered to import fentanyl-related compounds (drug code 9850, Schedule I). The company plans to import these substances only as part of a manufacturing process supporting research and clinical trials, and the registration would not authorize import of FDA-approved or non-approved finished dosage forms for commercial sale.
Comments and hearing deadline: Feb 27, 2025
Registered bulk manufacturers of the affected basic class(es) and applicants may submit electronic comments or objections through https://www.regulations.gov, or file a written request for a hearing, on or before February 27, 2025. Hearing requests must also be mailed to specified DEA hearing and Federal Register addresses in Springfield, Virginia.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-01766, Importer of Controlled Substances Application: Aveva Drug Delivery Systems, Inc.
Aveva Drug Delivery Systems, Inc. wants to become an official importer of certain controlled drugs, including Thebaine. People and companies involved with these drugs can share their thoughts or ask for a hearing by February 27, 2025. This move could impact drug supply chains and regulatory oversight but doesn’t mention any costs yet.
Next: 2025-01768, City of Hamilton, Ohio and American Municipal Power, Inc.; Notice of Application Accepted for Filing and Soliciting Motions To Intervene and Protests
The City of Hamilton, Ohio, and American Municipal Power want a new license to run the Greenup Hydroelectric Project on the Ohio River near Ohio and Kentucky. This affects local communities and energy users by potentially changing how power is generated there. People have 60 days to speak up, join in, or protest before the project moves forward.